Cargando…

Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach

BACKGROUND: The currently recommended dose of rituximab for primary membranous nephropathy is as high as that for lymphoma. However, the clinical manifestations of membranous nephropathy vary widely. Therefore, achieving individualized treatment is a topic that needs to be explored. This study asses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Song, Deng, Zhenling, Wang, Yue, Bao, Wenhan, Zhou, Sijia, Cui, Zhuan, Zheng, Danxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213597/ https://www.ncbi.nlm.nih.gov/pubmed/37237260 http://dx.doi.org/10.1186/s12882-023-03206-1

Ejemplares similares

Idiopathic multicentric Castleman disease with Sjögren’s syndrome and secondary membranous nephropathy: a case report and review of the literature
por: Pan, Yuejuan, et al.
Publicado: (2020)

Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Efficacy and Safety of Rituximab in Hepatitis B Virus–Associated PLA2R-Positive Membranous Nephropathy
por: Berchtold, Lena, et al.
Publicado: (2017)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
por: Xue, Cheng, et al.
Publicado: (2023)

The cutoff value and prognosis of anti-PLA2R antibody for idiopathic membranous nephropathy: a single-center retrospective study in China
por: Guo, Hongxia, et al.
Publicado: (2023)

Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report
por: Wang, Xiao-Pei, et al.
Publicado: (2016)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy
por: Cheng, Yan-jiao, et al.
Publicado: (2023)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2022)

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort
por: Gao, Shuang, et al.
Publicado: (2021)

Correction: The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy
por: Cheng, Yan-jiao, et al.
Publicado: (2023)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Horseshoe kidney with PLA2R-positive membranous nephropathy
por: Shi, Shuai-Shuai, et al.
Publicado: (2021)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy
por: Teisseyre, Maxime, et al.
Publicado: (2021)

Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Anti-PLA(2)R Antibodies in Chinese Patients with Membranous Nephropathy
por: Li, Xin, et al.
Publicado: (2016)

Membranous nephropathy PLA2R+ associated with Chagas disease
por: Xavier-Júnior, José Cândido Caldeira, et al.
Publicado: (2015)

The Role of PLA2R Antibody in Treatment of Membranous Nephropathy
por: Dahan, Karine, et al.
Publicado: (2017)

PLA2R antibodies and PLA2R glomerular deposits in psoriasis patients with membranous nephropathy
por: Ge, Yong-Chun, et al.
Publicado: (2016)

Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
por: Wang, Yao-Wei, et al.
Publicado: (2023)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Favorable outcome in PLA2R positive HBV-associated membranous nephropathy
por: Chen, Ruiying, et al.
Publicado: (2022)

Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial
por: Brglez, Vesna, et al.
Publicado: (2020)

Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy
por: Geara, Abdallah S., et al.
Publicado: (2021)

Concurrent PLA2R-Associated Membranous Nephropathy and Antiglomerular Basement Membrane Disease
por: Jagannathan, Geetha, et al.
Publicado: (2022)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study
por: Chen, Xian, et al.
Publicado: (2023)

Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy
por: Cheong, Jamie, et al.
Publicado: (2018)

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy
por: Cheungpasitporn, Wisit, et al.
Publicado: (2016)

Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023)

The place of cyclical therapy for the treatment of membranous nephropathy in the era of rituximab
por: Alberici, Federico, et al.
Publicado: (2023)

The application of podocyte antigen PLA2R and anti-PLA2R antibody in the diagnosis and treatment of membranous nephropathy
por: Chen, Yang, et al.
Publicado: (2023)

Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy
por: Logt, Anne-Els van de, et al.
Publicado: (2021)

Efficacy and Safety of Different Immunosuppressive Therapies in Patients With Membranous Nephropathy and High PLA2R Antibody Titer
por: Deng, Le, et al.
Publicado: (2022)

Low serum IgG4 level: a potential diagnostic biomarker for IgA nephropathy
por: Tian, Xinyu, et al.
Publicado: (2021)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
por: Lin, Jamie S, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q1d11hc9ge81iiccnd4o9u5c0i